Oral capecitabine plus subcutaneous interferon alpha in advanced squamous cell carcinoma of the skin

Wollina, Uwe; Hansel, Gesina; Koch, Andreas; Köstler, E

doi:10.1007/s00432-004-0656-6

Cited by 63 publications

(41 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The final outcome was complete remission in two patients and progressive disease in one patient; however, the authors state that controlled trials are necessary to prove the benefit observed in this series. 37 Capecitabine is a prodrug of 5-deoxy-5-fluorouridine. It is metabolized in the liver to 5-FU by thymidine phosphorylase, which is overexpressed in some human carcinomas.…”

Section: Capecitabinementioning

confidence: 99%

Skin cancer in solid organ transplant recipients: Advances in therapy and management

Zwald

Brown

2011

Journal of the American Academy of Dermatology

253

View full text Add to dashboard Cite

Section: Capecitabinementioning

confidence: 99%

Skin cancer in solid organ transplant recipients: Advances in therapy and management

Zwald

Brown

2011

Journal of the American Academy of Dermatology

253

View full text Add to dashboard Cite

“…Wollina et al [19] used oral capecitabine and s.c. IFN-␣ in four patients with advanced cutaneous SCC. Capecitabine is an orally bioavailable fluoropyrimidine chemotherapy agent that is converted to 5-FU in tumor cells.…”

Section: Cytotoxic Chemotherapymentioning

confidence: 99%

Treatment of Unresectable and Metastatic Cutaneous Squamous Cell Carcinoma

2010

View full text Add to dashboard Cite

Cutaneous squamous cell carcinoma (SCC) is an already common disorder with a rapidly increasing incidence. Treatment of early disease depends primarily on surgery or destructive techniques. In contrast to the frequency of early SCC, unresectable or metastatic SCC is relatively rare, but potentially life-threatening without clearly proven treatment options. Few rigorous studies of the treatment of advanced SCC have been undertaken. In the past, various agents have been explored in a limited fashion, including chemotherapy (cisplatin, fluoropyrimidines, bleomycin, doxorubicin), 13-cis-retinoic acid, and interferon-␣2a. Clinical activity has been suggested by these trials, but their small sizes, heterogeneous patient populations, and lack of randomization have hindered the use of their results in defining treatment paradigms. Only one rigorous randomized trial has focused on cutaneous SCC. Enrolling 66 patients, that trial randomized patients at high recurrence risk to either observation or postoperative interferon-␣2a and 13-cis-retinoic acid. This treatment did not improve time to recurrence or prevent secondary cutaneous SCC from developing. Though not in the metastatic setting, this study casts doubt on the ability of this regimen to control metastatic disease. Recently, agents targeting the human epidermal growth factor receptor (erlotinib, gefitinib, cetuximab) have displayed preliminary evidence of activity in phase II clinical trials and case series reports. Expression of this receptor is frequent in cutaneous SCC and appears to be prognostically adverse. Only the conduct of rigorous trials, with well-defined endpoints, adequate patient numbers, and preferably randomization, can prove the clinical efficacy of this promising treatment approach and define better therapy for this vexing clinical problem. The Oncologist 2010;15:1320 -1328

show abstract

“…Wollina et al [ 17 ] performed a prospective case series of four patients with advanced CSCC treated with oral capecitabine plus subcutaneous interferon alpha, of which two patients had complete response and two a partial response. Of note, the patients had only mild side effects.…”

Section: Induction and Defi Nitive Chemotherapy For Advanced Csccmentioning

confidence: 98%

Management of Widely Metastatic and Unresectable Cutaneous Squamous Cell Carcinoma

Hanna

Ruiz

Lorch

2016

High-Risk Cutaneous Squamous Cell Carcinoma

View full text Add to dashboard Cite

Oral capecitabine plus subcutaneous interferon alpha in advanced squamous cell carcinoma of the skin

Abstract: The treatment protocol with a combination of capecitabine and interferon alpha seems to be effective and well tolerated in patients with advanced SCC. Controlled trials are necessary to prove the benefit we observed in this case series.

Cited by 63 publications

References 22 publications

Skin cancer in solid organ transplant recipients: Advances in therapy and management

Skin cancer in solid organ transplant recipients: Advances in therapy and management

Treatment of Unresectable and Metastatic Cutaneous Squamous Cell Carcinoma

Management of Widely Metastatic and Unresectable Cutaneous Squamous Cell Carcinoma

Contact Info

Product

Resources

About